JUN 13, 2020 12:14 PM PDT

Examining Cancers Effect on the Immune System for Prognostic Use

WRITTEN BY: Jasper Cantrell

Most think of cancer in the context of where it is on the body like breast or pancreatic cancer. There are several more ways of broadly classifying cancers, however. One such way is how cancer can influence the environment around them, in particular how it affects the immune system. By examining the tumor immune microenvironment (TIME), a doctor or researcher could obtain valuable prognostic information. Three general TIME groups have been identified. An anti-tumor TIME group characterized by a relatively high number of anti-cancer immune cells, a pro-tumor TIME group characterized by a lack of anti-tumor immune cells and a high number of immune-suppressing cells and a third group is an immune-absent group characterized by the lack of an immune response overall.

A team from the Research Center of Borstel in Germany took an interest in these TIME groups and began an investigation. Their goal was to identify any genes or other factors that were unique to each TIME group. They pulled the data of 155 head and neck squamous cell carcinomas (HNSCC) patients from The Cancer Genome Atlas (TCGA) and began their investigations.

The team defined TIME groups based on their expression of genes related to the cytotoxic T-cell response. An immune-activated TIME group would have elevated expression, an immune-suppressed TIME group would have lower expression, and an immune absent TIME group would have a lower expression of all immune-related genes. Examining the patient data, the immune-activated TIME group had a higher overall survival rate over the other two groups. Patients with late-stage tumors were far more likely to be in the immune-suppressed TIME group than any other group. They also found a tumor’s histology, or a tumor’s structure, was more likely to be similar amongst patients of the same group.

The team then began to look at possible gene mutations in each group that were unique. The standout genes were TP53, which had a strong correlation with the immune absent TIME group, and EP300, which correlated with the immune-activated TIME group. They decided to follow up on EP300.  A quick analysis of TCGA data showed that EP300 mutations correlated with the immune-activated TIME group of gastric, prostate, and esophageal squamous cell carcinomas as well as HNSCC. EP300 is also known to increase the expression of glycolytic genes. Glycolysis is an inefficient energy production method used when oxygen is not available. It also produces lactic acid, which can act as a suppressor of the immune system. Mutations in EP300 would reduce the amount of lactic acid in tumor cells, and promote an anti-tumor TIME.

The group’s efforts revealed that the TIME of a tumor might indeed have prognostic value. Unique genetic biomarkers for TIME were scarce, unfortunately. TP53 is already linked to the regulation of the anti-tumor immune response, but EP300 was less understood. In silico analyses showed it was strongly linked to the anti-cancer immune response, with mutations in EP300 resulting in an immune-active TIME. The study of alternative pan-cancer types may one day allow for a better understanding of why certain drugs and therapies work on some cancer subtypes but not others. TIME grouping has promise, but much more research is needed before it can be considered a strong argument one way or another.

Sources: Nature, Nature Video
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 26, 2021
Cancer
COVID-19 Vaccination Induces Strong Immunity in Cancer Patients
AUG 26, 2021
COVID-19 Vaccination Induces Strong Immunity in Cancer Patients
Cancer patients have a higher risk of developing severe symptoms from a COVID-19 infection.   Many cancer pati ...
OCT 25, 2021
Cell & Molecular Biology
The Labroots 2021 Cell Biology Virtual Event Poster Winner: 5-Azacytidine Treatment & Lung Cancer
OCT 25, 2021
The Labroots 2021 Cell Biology Virtual Event Poster Winner: 5-Azacytidine Treatment & Lung Cancer
Labroots virtual events are a great place to share research and learn about others work. These events feature participan ...
NOV 25, 2021
Cancer
Could an Anti-Cancer Drug Treat Diabetes?
NOV 25, 2021
Could an Anti-Cancer Drug Treat Diabetes?
Diabetes and cancer are two common diseases that share many similar risk factors. People with diabetes are also at& ...
DEC 31, 2021
Cell & Molecular Biology
Cells Found to Release Super Small Bioactive Particles Called Supermeres
DEC 31, 2021
Cells Found to Release Super Small Bioactive Particles Called Supermeres
We know that cells are constantly secreting molecules that can have many different biological impacts; the term extracel ...
JAN 03, 2022
Cancer
Heating Up the Immune Response: Turning Cold Tumors Hot
JAN 03, 2022
Heating Up the Immune Response: Turning Cold Tumors Hot
Immune checkpoints are present on the surface of immune cells throughout the body.  Under normal conditions, they r ...
JAN 07, 2022
Drug Discovery & Development
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
JAN 07, 2022
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
This week, 23andMe, the consumer genetic testing giant, announced that it has begun a phase 1 clinical trial o ...
Loading Comments...